<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972123</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0081</org_study_id>
    <secondary_id>Protocol Version 3/13/2021</secondary_id>
    <secondary_id>A534225</secondary_id>
    <secondary_id>SMPH/MEDICINE/CARDIOLOGY</secondary_id>
    <nct_id>NCT04972123</nct_id>
  </id_info>
  <brief_title>The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope</brief_title>
  <official_title>The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syncope is defined as transient loss of consciousness associated with inability to maintain&#xD;
      postural tone with rapid and spontaneous recovery. The purpose of this study is to assess the&#xD;
      effects of sublingual administration of a new medication called CPC on tilt-induced syncope&#xD;
      in patients with a history of vasovagal syncope (VVS). 132 participants will be enrolled at&#xD;
      the University of Wisconsin - Madison. Each participant will be in the study for 1 day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasovagal syncope (VVS) is the most common type of syncope. The mechanism is reflex-mediated&#xD;
      triggered by various afferent input to the brain. The event is usually preceded by&#xD;
      diaphoresis, warmth, nausea, and pallor, and is followed by fatigue. While several drugs are&#xD;
      indicated in the treatment of VVS, to our knowledge, there is no current treatment of an&#xD;
      impending syncopal attack. In the present study, the investigators hypothesize that a single&#xD;
      administration of sublingual CPC preparation during the prodromal phase aborts tilt-induced&#xD;
      syncope or near syncope with SBP less than or equal to 70 mmHg in patients with a history of&#xD;
      VVS. Patients with an established diagnosis of typical VVS will be randomized to receive CPC&#xD;
      or placebo in 1:1 ratio. Drug or placebo will be administered at the onset of prodromes&#xD;
      during tilt table testing. In addition to the primary endpoint (syncope or near syncope with&#xD;
      SBP less than or equal to 70 mmHg), the investigators will be assessing the effects of the&#xD;
      drug on time to event, incidence of asystole (&gt; 3 sec), and fatigue after tilt table testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomized 1:1 to CPC or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who have hypotensive syncope or near syncope with SBP less than or equal to 70 mmHG during tilt test</measure>
    <time_frame>During tilt table testing (up 35 minutes)</time_frame>
    <description>Hypotensive syncope is defined as transient loss of consciousness associated with SBP less than or equal to 90 mmHg. Near syncope is defined as sensation of &quot;near fainting&quot; while still being responsive to verbal commands. Near syncope will be used as a primary endpoint only when it is associated with a SBP less than or equal to 70 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to syncope or near-syncope after CPC or placebo administration</measure>
    <time_frame>During tilt table testing (up 35 minutes)</time_frame>
    <description>Time in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who have asystolic pauses &gt; 3 sec in the CPC and placebo arms</measure>
    <time_frame>During tilt table testing (up 35 minutes)</time_frame>
    <description>Asystole will be defined as absence of QRS complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Score at 1, 4, and 8 hours post tilt table testing</measure>
    <time_frame>Up to 8 hours after tilt table testing</time_frame>
    <description>Self report of fatigue on a 1-5 scale where higher numbers indicate increased fatigue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Syncope, Vasovagal</condition>
  <arm_group>
    <arm_group_label>CPC Adminstration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of CPC will be given during tilt table test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Adminstration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of Placebo will be given during tilt table test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPC - Capsaicin, Phenylephrine, Caffeine</intervention_name>
    <description>CPC is a combination of Capsaicin, Phenylephrine and Caffeine</description>
    <arm_group_label>CPC Adminstration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tilt Table Test</intervention_name>
    <description>Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitrogylcerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).</description>
    <arm_group_label>CPC Adminstration</arm_group_label>
    <arm_group_label>Placebo Adminstration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for CPC</description>
    <arm_group_label>Placebo Adminstration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Established diagnosis of typical vasovagal syncope&#xD;
&#xD;
          2. Age 18-50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systolic BP &gt;130 mmHg&#xD;
&#xD;
          2. History of hypertension or cardiac arrhythmias&#xD;
&#xD;
          3. History of cardiovascular disease or cerebral ischemic events&#xD;
&#xD;
          4. Allergic reaction to any of the drug components&#xD;
&#xD;
          5. Contraindication to tilt testing&#xD;
&#xD;
          6. Any physical or psychological symptom, based on the clinical judgment of the&#xD;
             investigators that would make a participant unsuitable for the study&#xD;
&#xD;
          7. Any use of a medication(s) based on the clinical judgment of the investigators that&#xD;
             would make a participant unsuitable for the study (e.g. fludrocortisone, theophylline,&#xD;
             prazosin, doxazosin, terazosin, MAO-inhibitors, pseudoephedrine, decongestant and PDE5&#xD;
             inhibitors).&#xD;
&#xD;
          8. Unwilling to discontinue Midodrine or beta-blocker therapy 48 hours before tilt table&#xD;
             testing.&#xD;
&#xD;
          9. Women who are pregnant (confirmed with pregnancy test on day of study) or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed H Hamdan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed H Hamdan, MD</last_name>
    <phone>608-263-1532</phone>
    <email>mhamdan@medicine.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassondra A Vander Ark, MS</last_name>
    <phone>608-265-0612</phone>
    <email>cav@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin- Madsion</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed H Hamdan, MD</last_name>
      <phone>608-263-1532</phone>
      <email>mhamdan@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cassondra A Vander Ark, MS</last_name>
      <phone>608-265-0612</phone>
      <email>cav@medicine.wisc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bartoletti A, Alboni P, Ammirati F, Brignole M, Del Rosso A, Foglia Manzillo G, Menozzi C, Raviele A, Sutton R. 'The Italian Protocol': a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope. Europace. 2000 Oct;2(4):339-42.</citation>
    <PMID>11194602</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurocardiogenic Syncope</keyword>
  <keyword>Reflex Syncope</keyword>
  <keyword>Fainting Spells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

